Conservation of HHV-6 DNA polymerase processivity factor sequence and predicted structure suggests it as a target for antiviral development by Bonnafous, Pascale et al.
SC
p
P
A
a
b
c
d
e
a
A
R
R
A
K
H
U
D
A
a
h
h
c
h
(
v
b
f
v
S
c
t
t
U
(
P
T
0
dAntiviral Research 86 (2010) 316–319
Contents lists available at ScienceDirect
Antiviral Research
journa l homepage: www.e lsev ier .com/ locate /ant iv i ra l
hort communication
onservation of HHV-6 DNA polymerase processivity factor sequence and
redicted structure suggests it as a target for antiviral development
ascale Bonnafousa,∗, Moira Verbelena, Stéphanie Petrellab, Claire Debacka,c,
gnès Gautheret-Dejeana,c,d, David Boutolleaua,c, Lieve Naesense, Henri Aguta,c
UPMC Univ Paris 06, ER1 DETIV, Laboratoire de Virologie, F-75013 Paris, France
UPMC Univ Paris 06, ER 5, Bactériologie-Hygiène, F-75013 Paris, France
Laboratoire de Virologie, Groupe hospitalier Pitié-Salpêtrière, APHP, 75013 Paris, France
Laboratoire de Microbiologie, Faculté des Sciences Pharmaceutiques et Biologiques, 75006 Paris, France
Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
r t i c l e i n f o
rticle history:
eceived 1 December 2009
eceived in revised form 4 March 2010
ccepted 10 March 2010
eywords:
a b s t r a c t
The replication of human herpesvirus-6 (HHV-6) DNA is catalyzed by the viral DNApolymerase pU38 and
theprocessivity factorpU27whichstabilizes theenzymeontheDNAtemplate. Thegeneticpolymorphism
of pU27 among 46 clinical strains of HHV-6 variant A or B and four strains resistant to antivirals was
investigated. Overall, 28 amino acid changes (7.6%) and a two-amino acid deletionwere identiﬁed among
the 368 residues of pU27, when using the U1102 (variant A) sequence as the reference. Eleven amino acidHV-6
27
NA polymerase
ntiviral
changes (3.0%) speciﬁcally differentiated both variants. The median intravariant amino acid variability
was 1.2% and 0.3% for A and B, respectively. Except for a single change, the pU27 sequence of multi-drug
resistant HHV-6 strains was also conserved. Structural models of pU27 for variants A and B were derived
from that of the human cytomegalovirus homologue pUL44, and showed either identical or very similar
residues in the regions interacting with viral DNA polymerase and viral DNA molecule. As pU27 is both
highly conserved and essential for viral replication, it might constitute an interesting target for antiviral
chemotherapy.
Human herpesvirus-6 (HHV-6), which exists as two variants A
ndB (HHV-6A andHHV-6B), is a betaherpesvirus closely related to
umancytomegalovirus (HCMV). It is lympho- andneurotropic and
as been recognized as a major pathogen, especially in immuno-
ompromised patients (De Bolle et al., 2005). Moreover, HHV-6
as been implicated in various central nervous system diseases
Komaroff et al., 2006). No consensual speciﬁc therapeutic inter-
entionhas been established for the treatment ofHHV-6 infections,
ut drugs also used against HCMV, i.e. ganciclovir (GCV), cido-
ovir (CDV) and foscarnet (PFA), have proven their efﬁciency in
arious HHV-6 related disorders (Dewhurst, 2004; Ljungman and
ingh, 2006). All these drugs target the viral DNA polymerase,
onsequently inhibiting viral replication. As for all herpesviruses,
he DNA polymerase complex of HHV-6 consists of two subunits,
he DNA polymerase which is the catalytic subunit encoded by
38 gene and a processivity factor, the product of the U27 gene
Agulnick et al., 1993; Chang and Balachandran, 1991). Initially
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namedp41, this 41-kDaprocessivity factor contains 368 residues in
the U1102 strain of HHV-6 variant A. It binds to both DNA template
and DNA polymerase, allowing synthesis of extended stretches of
DNAwithoutdissociationof the catalytic subunit fromthe template
(Lin and Ricciardi, 1998). The binding between pU27 and pU38 is
speciﬁc of the viral species, and has been demonstrated both in
vitro, by protein coimmunoprecipitation assays, and in infected
cells (Lin and Ricciardi, 1998). It has also been shown, by means
of mutational analysis, that both the 77 N-terminal and the 235
C-terminal residues of pU38 contribute to its binding to pU27 and
DNA synthesis. In the case of pU27, the 130 N-terminal amino acids
were required for binding to pU38 and then increasing DNA syn-
thesis, of which the ﬁrst 30 residues were apparently essential for
increasing DNA synthesis, whereas the last 31 C-terminal residues
were totally dispensable. Similar interactions between the pro-
cessivity factors and DNA polymerases from herpes simplex virus
(HSV) orHCMVhave beendemonstrated and shown to be essential,
since disruption of the protein-protein interaction inhibits virus
replication (Loregian and Palù, 2005). Furthermore, crystallization
of the processivity factors of these two herpesviruses, pUL42 and
pUL44, respectively, has shown that they share the same structure
with a connector loopbinding to theDNApolymerasebyhydropho-
bic interactions or hydrogen bonds (Appleton et al., 2004; Zuccola
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Table 1
Primers used to amplify and sequence the HHV-6 U27 gene.
Primer Sequence 5′→3′ (orientation) Locationa Use
U27A AAG GCG CGA GTT GGT GCT AGG (+) 39897-39877 PCR, sequencing
U27Abis AAA GCA CAT AAG GCG CGA GTT GGT (+) 39906-39883 PCR, sequencing
U27A1 CGA ATC CTG AGG TTA CGA AG (+) 39530-39511 Sequencing
U27A2 CTG CCA AAA ATT TAC AGC AGG C (+) 39161-39140 Sequencing
U27B GGA ATA ACG GCA CCC TTA GCA AG (−) 38737-38715 PCR, sequencing
U27Bbis GAA TAA CGG CAC CCT TAG CAA GAC C (−) 38740-38716 PCR, sequencing
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sU27B1 CCG TCA ACA ACG TGC TTT TGG AAG (−)
U27B2 ACC GAC GCC TGT GTA CAT GTA TC (−)
a Refers to the nucleotide sequence of the HST strain (accession number AB02150
t al., 2000). As far as HHV-6 pU27 is concerned, little is known
bout its interstrain variability, its interactions with pU38 and viral
NA, and its putative role in the resistance of HHV-6 to antivirals.
n this study, the U27 gene of 46 strains of HHV-6A or HHV-6B was
equenced to determine its natural polymorphism. Four mutant
trains of HHV-6B selected in vitro and resistant to GCV, PFA and/or
DV were also examined. Finally, using the available crystal struc-
ure of pUL44 from HCMV, a structural model of pU27 was built in
rder to better understand the interactions of the HHV-6 proces-
ivity factor with the DNA polymerase and the DNA molecule.
. Intervariant and intravariant polymorphism of pU27
In this study, 46 HHV-6 strains (16 HHV-6A and 30 variants
HV-6B)were examined. The DNA from strains previously isolated
nd propagated in cell culture, i.e. U1102, GS, SIE, TAN, HST, BLA,
LE, BOU, TRA, BOB, MAR, MBE strains (Manichanh et al., 2001),
nd the DNA from HHV-6 positive clinical blood samples from dis-
inct patients (12 HHV-6A and 21 HHV-6B) were extracted using
ither the rapid lysis method as previously described (Bonnafous
t al., 2007) or the QIAamp DNA Blood kit (Quiagen, Courtaboeuf,
rance). The full-length U27 gene was then ampliﬁed by a one-
tep PCR for isolated strains and clinical samples with a viral load
ig. 1. Consensus protein sequence of HHV-6A and HHV-6B. Nucleotide sequencing was
equence (U27 cs A) was established from the sequences of U1102, SIE, TAN, GS strains
equence (U27 cs B) was established from the sequences of HST, BLA, BLE, BOU, TRA, BO
trains from patient blood samples. HHV-6B amino acids identical to HHV-6A are repres
pen and closed circles indicate an intravariant A and intravariant B variability, respective
tructural model.39062-39039 Sequencing
39456-39434 Sequencing
egawa et al., 1999).
higher than 2.25×105 copies of viral DNA per mL of blood using
the TaKaRA LA TaqTM kit (Lonza, Verviers, Belgium) and the U27A
and U27B primers (Table 1). The thermal cycling reaction con-
sisted of 94 ◦C for 5min, followed by 38 cycles at 94 ◦C for 1min,
59 ◦C for 1min, 72 ◦C for 1min 50 s and ﬁnally 72 ◦C for 10min.
A nested PCR was performed for the other extracts with a lower
DNA load, using the U27Abis and U27B primers for the ﬁrst step,
and the U27A and U27Bbis primers for the second step, under
the same PCR conditions, except that the annealing temperature
was 56.8 ◦C. PCR products were sequenced with the BigDye v3.1
Cycle Sequencing kit (Applied Biosystems, Courtaboeuf, France)
using the primers speciﬁed in Table 1. The nucleotide and derived
amino acid sequences were analyzed with Seqscape 2.5 software
and then aligned using Genedoc software. The U27 sequence of
strain Z29 (HHV-6B) was also included in this alignment (GenBank
accession number AF157706). For both HHV-6A and HHV-6B, the
obtained sequences were compared with each other and an amino
acid consensus sequence was established (Fig. 1). Among all strains
sequenced, 74 point mutations on 1107 nucleotides (6.7%), leading
to28changeson368aminoacids (7.6%)were identiﬁed. Inaddition,
a deletion of six nucleotides at the C-terminal end (1071–1076)
causing a two-amino acid deletion (N358-P359) was found in eight
sequences out of 16 HHV-6A strains. The same deletion was also
performed on DNA ampliﬁed from 46 HHV-6 strains. The consensus HHV-6A U27
and 12 HHV-6A strains from patient blood samples. The consensus HHV-6B U27
B, MAR, MBE, Z29 (GenBank accession number AF157706) strains and 21 HHV-6B
ented by a dash; the asterisk indicates the absence of an amino acid residue. The
ly. The black triangles indicate the lysine residues located in the four helices of the
3 ral Research 86 (2010) 316–319
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Fig. 2. Structural models of consensus HHV-6A and HHV-6B pU27 in comparison
with the structuresofHCMVpUL44andHSVpUL42.Ribbondiagramrepresentations
of HHV-6A pU27 (pU27-csA), HHV-6B pU27 (pU27-csB), HCMV pUL44 template
[Protein Data Bank (PDB) accession number 1yyp (Appleton et al., 2006)] and HSV
pUL42 [Protein Data Bank (PDB) accession number 1dml (Zuccola et al., 2000)] are
shown in red, orange, green, and blue, respectively. The models of pU27-csA and
pU27-csB were generated from the consensus amino acid sequences of HHV-6A
andHHV-6B, respectively, from residue 23 to residue 281, using the crystallographic
the positions 32, 35, 39, 42, 46, 49, 173, 180, 235 and 248, were
conserved among HHV-6A and HHV-6B strains (Fig. 1). These basic
residues, as for other processivity factors, would interact with the
negatively charged backbone of DNA. Interestingly, the pU27 pro-18 P. Bonnafous et al. / Antivi
resent in all HHV-6B strains. Of all mutations, 37 nucleotide posi-
ions (3.3%) and 11 amino acids (3.0%) were variant-speciﬁc and
llowed discrimination between the two variants of HHV-6. Of
ote, the present study conﬁrmed the divergence at position 328,
etweenvariants A (serine) andB (asparagine), that previously per-
itted to deﬁne a monoclonal antibody speciﬁc for HHV-6A (Xu et
l., 2001). The median intravariant HHV-6A nucleotide variability
as 1.1%, corresponding to a median amino acid variability of 1.2%.
he intravariantHHV-6Bvariabilitywas lower,with amedianvalue
f 0.2% in nucleotides and 0.3% in amino acids. This low variability
as within the same range as the divergence of homologous UL44
ene among HCMV strains, with an interstrain variability ranging
rom0.5% to 1.5% at the nucleotide level and being less than 0.5% for
mino acid residues (Boutolleau et al., 2009). These genes are part
f the most conserved genes in human herpesviruses, as expected
iven their essential role in replication.
In addition, four HST-derived strains, selected in vitro under
ncreasing concentrations of GCV, CDV and/or PFA,were also inves-
igated (Bonnafous et al., 2007, 2008). U27 gene sequences were
dentical to that of HST, except for one strain (GPFAR1 resistant
o GCV, CDV and PFA) that exhibited an a976g mutation leading
o an M326V change. It is assumed that this change either would
ot impact DNA synthesis or, at best, provide a beneﬁt in terms of
tness. Indeed, the growth of this resistant strain was found sim-
lar to that of wild-type HST despite the observed changes in the
iral DNA polymerase and phosphotransferase which are believed
o explain resistance pattern (Bonnafous et al., 2007, 2008). It is
nlikely that the M326V change would play a role in the resis-
ance to GCV, CDV and PFA since these drugs all target the catalytic
ite of DNA polymerase and are not expected to interfere with the
rocessivity factor.
. Three-dimensional structural model of the HHV-6
rocessivity factor
In order to identify the regions of pU27 important for binding to
U38 and viral DNA, models of the three-dimensional structure of
HV-6A and HHV-6B pU27 were generated with the homology-
odelling server SWISS-MODEL (Arnold et al., 2006; Guex and
eitsch, 1997; Kopp and Schwede, 2004), starting from consen-
us amino acid sequences and using the crystallographic protein
tructure of processivity factor pUL44 of HCMV as the template
Protein Data Bank (PDB) accession number 1yyp] (Appleton et al.,
006). The two structures obtained were energy-minimized in 100
teps using the program CNS and visualized using PyMOL (Brünger
t al., 1998; DeLano, 2002). As the entire pUL44 protein has not
een crystallized, the structure of pU27 was derived from residue
3 to residue 281 (Fig. 2). Furthermore, the structure of a short
art of pUL44 (residues 163–174) has not been determined and
he corresponding part of pU27 (residues 182–192) consequently
ormed a randomized loop. The pU27 models of both variants were
xtremely similar. It was also shown using PyMOL software that
he very modest intravariant changes did not induce any dramatic
ocal conformational change that could modify the interactions
ith DNA or DNA polymerase. As a whole, the processivity factor
f both HHV-6A and HHV-6B shares the same structure as HCMV
UL44andHSVpUL42, i.e. two topologically similar domains linked
y a connector loop and four alpha helices located at the back side
Appletonet al., 2004; Zuccola et al., 2000). The sequenceof the con-
ector loop of pU27 was compared to that of pUL44 (Fig. 3). Most
mino acids were either identical or similar between both beta-
erpesvirus species, suggesting that the connector loop of pU27
nteracts with the polymerase pU38 in the same manner as pUL44
ith pUL54. In contrast, the sequence of the connector loop of HSV
UL42 was very different (data not shown). In addition, several
ysine residues, which were found in the four helices of pU27 atprotein structure of pUL44 as a template. The arrows indicate both ends of connector
loop (residues 144–155, 144–155, 129–140 and 160–175 for pU27-csA, pU27-csB,
pUL44 and pUL42, respectively). (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of the article.)Fig. 3. Connector loopsequencesofHHV-6ApU27,HHV-6BpU27, andHCMVpUL44.
The consensus HHV-6A and HHV-6B pU27 sequences were compared with HCMV
pUL44 sequence (AD169 strain, GenBank accession number BK000394). The open
circle indicates a position of intravariant A variability. The asterisks indicate the sim-
ilarity of amino acids. The residues crucial for the binding to pUL44DNApolymerase
are framed.
ral Res
t
f
R
o
a
p
p
c
2
c
s
f
t
p
p
t
w
r
s
c
C
t
n
d
R
A
A
A
A
BP. Bonnafous et al. / Antivi
ein deleted of the 30 N-terminal and 31 C-terminal residues was
ound to bind to pU38 but failed to increase DNA synthesis (Lin and
icciardi, 1998). It is likely that this deletion in the N-terminus dis-
rganizes the structureofnearbyhelices containing lysine residues,
nd prevents the binding toDNA. However, the active formof pU27
rotein is yet unknown. Indeed, it might be a monomer like HSV
UL42, or, in contrast, a dimer forming a C clamp-shapewhereDNA
ould bind, as in HCMV pUL44 (Appleton et al., 2004; Zuccola et al.,
000). Only crystallization and analysis of the structure of pU27 in
omplex with DNA molecule may provide such information.
Because its sequence appears very constant and the proposed
tructural model suggests similar interactions to the processivity
actors of other herpesviruses, pU27 could constitute an interesting
arget for newantiviral drugs. Indeed, in the case ofHSV andHCMV,
eptidic compounds mimicking the C-terminal part of the DNA
olymerase, as well as diverse small molecules, were screened for
heir capability to interfere with the binding of processivity factor
ith DNA polymerase, and some were efﬁcient in inhibiting viral
eplication in infected cells (Loregian and Palù, 2005). Furthermore,
ome of them had an antiviral activity 500-fold higher than their
ytotoxicity, which reﬂected a high selectivity index (Loregian and
oen, 2006). In the same manner, although the precise identiﬁca-
ion of residues involved in pU27–pU38 interaction is still needed,
ew drugs aiming at the disruption of this interaction could be
eveloped.
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